Cosmo signed an exclusive US license agreement for Aemcolo with RedHill in return for a high twenty percent royalty on sales and milestones of up to USD 100 mn, while taking a 19.6% stake in RedHill. This follows Cosmo’s “equity for product” investment strategy, which reduces costs while retaining long-term value creation through its equity stake.

Key catalysts include:

  • Relafalk EU launch by Dr. Falk (Q4 2019)
  • MethyleneBlue EU launch (mid 2020)
  • GI Genius US approval & launch by Medtronic (end 2020)

Cosmo Valuation Report "Seeing is believing"